CL2011001309A1 - Protozoo parásito modificado que posee una expresión simultanea de al menos dos proteínas variables de superficie (vsp); vacuna que lo comprende; y uso. - Google Patents

Protozoo parásito modificado que posee una expresión simultanea de al menos dos proteínas variables de superficie (vsp); vacuna que lo comprende; y uso.

Info

Publication number
CL2011001309A1
CL2011001309A1 CL2011001309A CL2011001309A CL2011001309A1 CL 2011001309 A1 CL2011001309 A1 CL 2011001309A1 CL 2011001309 A CL2011001309 A CL 2011001309A CL 2011001309 A CL2011001309 A CL 2011001309A CL 2011001309 A1 CL2011001309 A1 CL 2011001309A1
Authority
CL
Chile
Prior art keywords
vaccine
surface proteins
vsp
simultaneous expression
variable surface
Prior art date
Application number
CL2011001309A
Other languages
English (en)
Inventor
Hugo Daniel Lujan
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecnicas Conicet Univ Catolica De Cordoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecnicas Conicet Univ Catolica De Cordoba filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecnicas Conicet Univ Catolica De Cordoba
Publication of CL2011001309A1 publication Critical patent/CL2011001309A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Protozoo parásito modificado que posee una expresión simultánea de más de una proteína variable de superficie; vacuna que lo comprende; procedimiento para purificar el repertorio total de proteínas de superficie variable de protozoos; método de inmunización; y secuencias de nucleótidos para silenciar los genes rdrp y dicer.
CL2011001309A 2008-12-02 2011-06-02 Protozoo parásito modificado que posee una expresión simultanea de al menos dos proteínas variables de superficie (vsp); vacuna que lo comprende; y uso. CL2011001309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11905808P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
CL2011001309A1 true CL2011001309A1 (es) 2012-03-16

Family

ID=42233679

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011001309A CL2011001309A1 (es) 2008-12-02 2011-06-02 Protozoo parásito modificado que posee una expresión simultanea de al menos dos proteínas variables de superficie (vsp); vacuna que lo comprende; y uso.
CL2018002834A CL2018002834A1 (es) 2008-12-02 2018-10-04 Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos (divisional solicitud 201101309)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018002834A CL2018002834A1 (es) 2008-12-02 2018-10-04 Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos (divisional solicitud 201101309)

Country Status (18)

Country Link
US (1) US9463229B2 (es)
EP (1) EP2364156B1 (es)
JP (3) JP2012510286A (es)
CN (1) CN102281884B (es)
AR (1) AR074458A1 (es)
AU (1) AU2009323734B2 (es)
BR (1) BRPI0917075B1 (es)
CA (1) CA2745470C (es)
CL (2) CL2011001309A1 (es)
CO (1) CO6390115A2 (es)
CR (1) CR20110377A (es)
EC (1) ECSP11011171A (es)
ES (1) ES2667773T3 (es)
MX (2) MX351579B (es)
NZ (2) NZ604943A (es)
PE (2) PE20150889A1 (es)
PT (1) PT2364156T (es)
WO (1) WO2010064204A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
EP4566624A1 (en) * 2023-12-04 2025-06-11 VacciMed-Oral GmbH Vaccines against protozoan parasites

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512288A (en) * 1992-12-04 1996-04-30 University Technologies International, Inc. Giardia vaccine
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
JP2000083677A (ja) * 1998-09-17 2000-03-28 Bayer Ltd ダニワクチン
GB0000474D0 (en) * 2000-01-10 2000-03-01 Inal Jameel M Receptor

Also Published As

Publication number Publication date
PT2364156T (pt) 2018-04-24
EP2364156A2 (en) 2011-09-14
AU2009323734B2 (en) 2016-06-30
AU2009323734A1 (en) 2010-06-10
EP2364156B1 (en) 2018-01-31
JP2012510286A (ja) 2012-05-10
CR20110377A (es) 2011-10-20
MX2011005815A (es) 2011-09-30
CN102281884A (zh) 2011-12-14
BRPI0917075B1 (pt) 2019-11-12
PE20150889A1 (es) 2015-06-07
US9463229B2 (en) 2016-10-11
CL2018002834A1 (es) 2019-04-05
CA2745470A1 (en) 2010-06-10
BRPI0917075A2 (pt) 2016-08-02
JP6793621B2 (ja) 2020-12-02
WO2010064204A2 (en) 2010-06-10
PE20110942A1 (es) 2011-12-30
NZ593106A (en) 2013-05-31
WO2010064204A3 (en) 2010-12-02
JP2016000045A (ja) 2016-01-07
ECSP11011171A (es) 2011-09-30
AR074458A1 (es) 2011-01-19
NZ604943A (en) 2014-08-29
CA2745470C (en) 2018-09-25
JP2018024700A (ja) 2018-02-15
CN102281884B (zh) 2015-09-30
ES2667773T3 (es) 2018-05-14
MX351579B (es) 2017-10-20
US20120093871A1 (en) 2012-04-19
CO6390115A2 (es) 2012-02-29

Similar Documents

Publication Publication Date Title
CY1124644T1 (el) Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριων
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
AR065559A1 (es) Aparato y metodo de fracturacion
AR080885A1 (es) Composiciones y metodo para rotura de fluidos de fracturacion hidraulica
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
ECSP12011685A (es) Inmunoconjugados dirigidos
CO6382137A2 (es) Oligonucleótidos inmunoestimuladores
EA201070888A1 (ru) Антитела и их производные
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CR20150088A (es) Anticuerpos anti-notch1 nrr
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
AR080872A1 (es) Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
CR20120244A (es) Inhibidores de la tirosina quinasa de bruton
MX2019008989A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
EA201390156A1 (ru) ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
MX2014006786A (es) Anticuerpos utiles para la inmunizacion pasiva de influenza.
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
ES2530578T3 (es) Cristales y cristales reticulados de Proteína A y métodos de uso de los mismos
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
MX2010003540A (es) Asignacion de secuencias de preámbulo.